nach oben

Breast Cancer Research and Treatment

Erschienen in:

01.09.2008 | Preclinical Study

Nipple aspirate fluids from women with breast cancer contain increased levels of group IIa secretory phospholipase A2

verfasst von: Ferdinando Mannello, Wenyi Qin, Weizhu Zhu, Laura Fabbri, Gaetana A. Tonti, Edward R. Sauter

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 2/2008

Einloggen, um Zugang zu erhalten

Abstract

Arachidonic acid, a bioactive molecule metabolized into prostaglandins and leukotrienes, contributes to cellular proliferation and tumor progression. Group IIa secretory phospholipase A2 (sPLA2-IIa) can facilitate arachidonate release from cellular phospholipids, suggesting its involvement in tumor evolution. Analysis of breast nipple aspirate fluid (NAF), a noninvasive research tool, allows the identification of biomarkers of breast cancer. We sought to determine whether sPLA2-IIa expression might be related to breast cancer development or progression. sPLA2-IIa expression was evaluated in NAF samples from 110 women (57 women with and 53 without breast cancer) using ELISA and western blotting; ultrastructural immunolocalization was performed in epithelial cells floating in NAF. Immunocytochemistry revealed that sPLA2-IIa is a constitutive intracellular protein suggesting that breast ductal cells synthesize and secrete the 14 kDa protein in NAF. Among all 110 subjects, sPLA2-IIa expression was significantly increased both in NAF and within ductal epithelial cells from cancer containing breasts. While in healthy women menopausal status did not influence sPLA2-IIa expression (P = 0.457), among patients with breast cancer there was a significant down-regulation in postmenopausal subjects (P < 0.0001). Moreover, sPLA2-IIa concentration in NAF from breast cancer patients was positively correlated with tumor stage (r ² = 0.979, P = 0.0012), suggesting an active secretion/accumulation of the enzyme in NAF based on tumor burden. sPLA2-IIa activity may serve a dual role in breast carcinogenesis, beneficial in its release of arachidonate and detrimental in the metabolic conversion of arachadonic acid into prostaglandins and leukotrienes.

Brash AR (2001) Arachidonic acid as bioactive molecule. J Clin Invest 107:1339–1345PubMedCrossRef

Six DA, Dennis EA (2000) The expanding superfamily of phospholipase A(2) enzymes: classification and characterization. Biochem Biophys Acta 1488:1–19PubMed

Diaz BL, Arm JP (2003) Phospholipase A₂. Prostaglandins Leukot Essent Fatty Acids 69:87–97PubMedCrossRef

Balsinde J, Winstead MV, Dennis EA (2002) Phospholipase A₂ regulation of arachidonic acid mobilization. FEBS Lett 531:2–6PubMedCrossRef

Touqui L (2001) Mammalian secreted phospholipases A2 and their pathophysiological significance in inflammatory diseases. Curr Mol Med 1:739–754PubMedCrossRef

Kugiyama K, Ota Y, Sugiyama S, Kawano H, Doi H, Soejima H, Miyamoto S, Ogawa H, Takazoe K, Yasue H (2000) Prognostic value of plasma levels of secretory type II phospholipase A2 in patients with unstable angina pectoris. Am J Cardiol 86:718–722PubMedCrossRef

Cormier RT, Hong KH, Halberg RB, Hawkins TL, Richardson P, Mulherkar R, Dove WF, Lander ES (1997) Secretory phospholipase PLA2 g2a confer resistance to intestinal tumorigenesis. Nat Genet 17:88–91PubMedCrossRef

Murata K, Egami H, Kiyohara H, Oshima S, Kurizaki T, Ogawa M (1993) Expression of group-II phospholipase A₂ in malignant and non-malignant human gastric mucosa. Br J Cancer 68:103–111PubMed

Leung SY, Chen X, Chu KM, Yuen ST, Mathy J, Ji J, Chan ASY, Li R, Law S, Troyanskaya OG, Tu IP, Wong J, So S, Botstein D, Brown PO (2002) Phospholipase A2 group IIa expression in gastric adenocarcinoma is associated with prolonged survival and less frequent metastasis. Proc Natl Acad Sci 99:16203–16208PubMedCrossRef

10.

Kiyohara H, Egami H, Kako H, Shibata Y, Murata K, Ohshima S, Sei K, Suko S, Kurano R, Ogawa M (1993) Immunohistochemical localization of group II phospholipase A₂ in human pancreatic carcinomas. Int J Pancreatol 13:49–57PubMed

11.

Kashiwagi M, Friess H, Uhl W, Berberat P, Abou-Shady M, Martignoni M, Anghelacopoulos SE, Zimmermann A, Buchler MW (1999) Group II and IV phospholipase A(2) are produced in human pancreatic cancer cells and influences prognosis. Gut 45:605–612PubMedCrossRef

12.

Ying Z, Tojo H, Komatsubara T, Nagakawa M, Inada M, Kawata S, Matsuzawa Y, Okamoto M (1994) Enhanced expression of group II phospholipase A₂ in human hepatocellular carcinoma. Biochim Biophys Acta 1226:201–205PubMed

13.

Kennedy BP, Soravia C, Moffat J, Xia L, Hiruki T, Collins S, Gallinger S, Bapat B (1998) Overexpression of the non-pancreatic secretory group II PLA₂ messenger RNA and protein in colorectal adenomas from familial adenomatous polyposis patients. Cancer Res 58:500–503PubMed

14.

Graff JR, Konicek BW, Deddens JA, Chedid M, Hurst BM, Colligan B, Neubauer BL, Carter HW, Carter JH (2001) Expression of group IIa secretory phospholipase A₂ increases with prostate tumor grade. Clin Cancer Res 7:3857–3861PubMed

15.

Yamashita S, Yamashita J, Ogawa M (1994) Overexpression of group II phospholipase A₂ in human breast cancer tissues is closely associated with their malignant potency. Br J Cancer 69:1166–1170PubMed

16.

Yamashita S, Yamashita J, Sakamoto K, Inada K, Nakashima Y, Murata K, Saishoji T, Nomura K, Ogawa M (1993) Increased expression of membrane-associated phospholipase A₂ shows malignant potential of human breast cancer cells. Cancer 71:3058–3064PubMedCrossRef

17.

Yamashita J, Ogawa M, Sakai K (1995) Prognostic significance of three novel biologic factors in a clinical trial of adjuvant therapy for node-negative breast cancer. Surgery 117:601–608PubMedCrossRef

18.

Hatala MA, Rayburn J, Rose DP (1993) Characterization of phospholipase A₂ activity in MDA-MB-435 human breast cancer cells. Cancer Lett 72:31–37PubMedCrossRef

19.

Yamashita S, Ogawa M, Sakamoto K, Abe T, Arakawa H, Yamashita J (1994) Elevation of serum group II phospholipase A₂ levels in patients with advanced cancer. Clin Chim Acta 228:91–99PubMedCrossRef

20.

Brueseke TJ, Bell JD (2006) A new hat for an old enzyme: waste management. Biochim Biophys Acta 1761:1270–1279PubMed

21.

Fuentes L, Hernandez M, Nieto ML, Crespo MS (2002) Biological effects of group IIA secreted phospholipase A₂. FEBS Lett 531:7–11PubMedCrossRef

22.

Chun KS, Surh YJ (2004) Signal transduction pathways regulating cyclooxygenase-2 expression: potential molecular targets for chemoprevention. Biochem Pharmacol 68:1089–1100PubMedCrossRef

23.

Meric JP, Rottey S, Olaussen K, Soria JC, Khayat D, Rixe O, Spano JP (2006) Cyclooxygenase-2 as a target for anticancer drug development. Crit Rev Oncol Hematol 59:51–64PubMedCrossRef

24.

Singh B, Lucci A (2002) Role of cyclooxygenase-2 in breast cancer. J Surg Res 108:173–179PubMedCrossRef

25.

Wang D, Dubois RN (2006) Prostaglandins and cancer. Gut 55:115–122PubMedCrossRef

26.

Cuendet M, Pezzuto JM (2000) The role of cyclooxygenase and lipooxygenase in cancer chemoprevention. Drug Metabol Drug Interact 17:109–157PubMed

27.

Howe LR, Dannenberg AJ (2003) COX-2 inhibitors for the prevention of breast cancer. J Mammary Gland Biol Neoplasia 8:31–43PubMedCrossRef

28.

Larkins TL, Nowell M, Singh S, Sanford GL (2006) Inhibition of cyclooxygenase-2 decreases breast cancer cell motility, invasion and matrix metalloproteinase expression. BMC Cancer 6:181PubMedCrossRef

29.

Mazhar D, Ang R, Waxman J (2006) Cox inhibitors and breast cancer. Br J Cancer 94:346–350PubMedCrossRef

30.

Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, Thun MJ (2006) Cancer statistics, 2006. CA Cancer J Clin 56:106–130PubMed

31.

Sauter ER, Ross E, Daly M, Klein-Szanto A, Engstrom PF, Sorling A, Malick J, Ehaya H (1997) Nipple aspirate fluid: a promising non-invasive method to identify cellular markers of breast cancer risk. Br J Cancer 76:494–501PubMed

32.

Alexander H, Stegner AL, Wagner-Mann C, Dubois GC, Alexander S, Sauter ER (2004) Proteomic analysis to identify breast cancer biomarkers in nipple aspirate fluid. Clin Cancer Res 10:7500–7510PubMedCrossRef

33.

Mannello F, Malatesta M, Sebastiani M, Battistelli S, Gazzanelli G (1999) Molecular forms and ultrastructural localization of prostate-specific antigen in nipple aspirate fluids. Clin Chem 45:2263–2266PubMed

34.

Qin W, Zhu W, Wagner-Mann C, Sauter ER (2003) Nipple aspirate fluid expression of urokinase-type plasminogen activator, plasminogen activator inhibitor-1, and urokinase-type plasminogen activator receptor predicts breast cancer diagnosis and advanced disease. Ann Surg Oncol 10:948–953PubMedCrossRef

35.

Mannello F, Sebastiani M (2003) Zymographic analyses and measurement of matrix metalloproteinase-2 and -9 in nipple aspirate fluids. Clin Chem 49:1546–1550PubMedCrossRef

36.

Mannello F, Tonti GAM, Pagliarani S, Benedetti S, Canestrari F, Zhu W, Qin W, Sauter ER (2007) The 8-epimer of prostaglandin F2α, a marker of lipid peroxidation and oxidative stress, is decreased in the nipple aspirate fluids of women with breast cancer. Int J Cancer 120:1971–1976PubMedCrossRef

37.

Fulton AM, Gimotty P, Alonsozana E, Dorsey R, Kundu N (2000) Elevated prostaglandin E2 (PGE2) levels in human breast cancer are associated with poor long-term survival. Proc Am Assn Cancer Res 41:3660A

38.

Harris RE, Beebe-Donk J, Alshafie GA (2006) Reduction in the risk of human breast cancer by selective cyclooxygenase-2 (COX-2) inhibitors. BMC Cancer 6:27PubMedCrossRef

39.

Singletary SE, Connolly JL (2006) Breast cancer staging: working with the sixth edition of the AJCC cancer staging manual. CA Cancer J Clin 56:37–47PubMedCrossRef

40.

Nevalainen TJ, Kortesuo PT, Rintala E, Marki F (1992) Immunochemical detection of group I and group II phospholipase A₂ in human serum. Clin Chem 38:1824–1829PubMed

41.

42.

Pechoux C, Boisgard R, Chanat E, Lavialle F (2005) Ca(2+)-independent phospholipase A2 participates in the vesicular transport of milk proteins. Biochim Biophys Acta 1743:317–329PubMedCrossRef

43.

Chan TA, Morin PJ, Vogelstein B, Kinzler KW (1998) Mechanisms underlying nonsteroidal antiinflammatory drug-mediated apoptosis. Proc Natl Acad Sci USA 95:681–686PubMedCrossRef

44.

Enomoto A, Murakami M, Kudo I (2000) Internalization and degradation of Type IIA phospholipase A(2) in mast cells. Biochem Biophys Res Commun 276:667–672PubMedCrossRef

45.

Thomas W, Coen N, Faherty S, Flatharta CO, Harvey BJ (2006) Estrogen induces phospholipase A₂ activation through ERK to mobilize intracellular calcium in MCF-7 cells. Steroids 71:256–265PubMedCrossRef

46.

Periwal SB, Farooq A, Bhargava VL, Bhatla N, Vij U, Murugesan K (1996) Effect of hormones and anti-hormones on phospholipase A₂ activity in human endometrial stromal cells. Prostaglandins 51:191–201PubMedCrossRef

47.

Farina MG, Billi S, Leguizamon G, Weissmann C, Guadagnoli T, Ribeiro ML, Franchi AM (2007) Secretory and cytosolic phospholipase A2 activities and expression are regulated by oxytocin and estradiol during labor. Reproduction 134:355–364PubMedCrossRef

48.

Kurusu S, Ishii S, Kawaminami M (2007) Changes in Rat uterine and cervicale phospholipase A2 activity following progesterone agonist and antagonist administration at term. J Reprod Dev 53:345–350PubMedCrossRef

49.

Sharma MR, Koltowski L, Ownbey RT, Tuszynski GP, Sharma MC (2006) Angiogenesis-associated protein annexin II in breast cancer: selective expression in invasive breast cancer and contribution to tumor invasion and progression. Exp Mol Pathol 81:146–156PubMedCrossRef

50.

Dong Q, Patel M, Scott KF, Graham GG, Russell PJ, Sved P (2006) Oncogenic action of phospholipase A2 in prostate cancer. Cancer Lett 240:9–16PubMedCrossRef

51.

Taylor PM, Woodfield RJ, Hodgkin MN, Pettitt TR, Martin A, Kerr DJ, Wakelam MJ (2002) Breast cancer cell-derived EMMPRIN stimulates fibroblast MMP2 release through a phospholipase A₂ and 5-lipoxygenase catalyzed pathway. Oncogene 21:5765–5772PubMedCrossRef

52.

Hernandez M, Burillo SL, Crespo MS, Nieto ML (1998) Secretory phospholipase A₂ activates the cascade of mitogen-activated protein kinases and cytosolic phospholipase A₂ in the human astrocytoma cell line 1321N1. J Biol Chem 273:606–612PubMedCrossRef

53.

Reddy KB, Glaros S (2007) Inhibition of MAP kinase activity suppresses estrogen-induced breast tumor growth both in vivo and in vitro. Int J Oncol 30:971–975PubMed

54.

Cuenda A, Rousseau S (2007) p-38 MAP-kinase pathway regulation, function and role in human diseases. Biochim Biophys Acta 1773:1358–1375PubMedCrossRef

55.

Funk CD (2001) Prostaglandins and leukotrienes: advances in eicosanoid biology. Science 294:1871–1875PubMedCrossRef

56.

Wolf I, O’Kelly J, Rubinek T, Tong M, Nguyen A, Lin BT, Tay HH, Karlan BY, Koeffler HP (2006) 15-Hydroxyprostaglandin dehydrogenase is a tumor suppressor of human breast cancer. Cancer Res 66:7818–7823PubMedCrossRef

57.

Diaz-Cruz ES, Brueggemeimer RW (2006) Interrelationship between cyclooxygenase and aromatase: unraveling the relevance of cyclooxygenase inhibitor in breast cancer. Anticancer Agents Med Chem 6:221–232PubMedCrossRef

58.

Sivula A, Talvensaari-Mattila A, Lundin J, Joensuu H, Haglund C, Ristimaki A, Turpeenniemi-Hujanen T (2005) Association of cyclooxygenase-2 and matrix metalloproteinase-2 expression in human breast cancer. Breast Cancer Res Treat 89:215–220PubMedCrossRef

59.

Kucab JE, Lee C, Chen CS, Zhu J, Gilks CB, Cheang M, Huntsman D, Yorida E, Emerman J, Pollak M, Dunn SE (2005) Celecoxib analogues disrupt Akt signaling, which is commonly activated in prim ary breast tumors. Breast Cancer Res 7:796–807CrossRef

60.

Barnes NL, Warneberg F, Farnie G, White D, Jiang W, Anderson E, Bundred NJ (2007) Cyclooxygenase-2 inhibition: effects on tumor growth cell cycling and lymphangiogenesis in a xenograft model of breast cancer. Br J Cancer 96:575–582PubMedCrossRef

61.

Sauter ER, Qin W, Schlatter L, Hewett J, Flynn TJ (2006) Celecoxib decreases prostaglandin E2 concentrations in nipple aspirate fluid from high risk popst-menopausal women and women with breast cancer. BMC Cancer 6:248PubMedCrossRef

62.

Natarajan R, Nadler J (1998) Role of lipooxygenase in breast cancer. Front Biosci 3:81–88

63.

Furstenberger G, Krieg P, Muller-Decker K, Habenicht AJ (2006) What are cyclooxygenases and lipooxygenases doing in the driver’s seat of carcinogenesis?. Int J Cancer 119:2247–2254PubMedCrossRef

64.

Chamras H, Ardashian A, Heber D, Glaspy JA (2002) Fatty acid modulation of MCF-7 human breast cancer cell proliferation, apoptosis and differentiation. J Nutr Biochem 13:711–716PubMedCrossRef

65.

Levine L (2004) Proteasome inhibitors: their effects on arachidonic acid release from cells in culture and arachidonic acid metabolism in rat liver cells. BMC Pharmacol 4:15PubMedCrossRef

66.

Avis I, Hong SH, Martinez A, Moody T, Choi YH, Trepel J, Das R, Jett M, Mulshine JL (2001) Five lipooxygenase inhibitors can mediate apoptosis in human breast cancer cell lines through complex eicosanoid interactions. FASEB J 15:2007–2009PubMed

67.

Leone S, Ottani A, Bertolini A (2007) Dual acting anti-inflammatory drugs. Curr Top Med Chem 7:265–275PubMedCrossRef

68.

Cakir Y, Plummer HK III, Tithof PK, Schuller HM (2002) Beta-adrenergic and arachidonic acid-mediated growth regulation of human breast cancer cell lines. Int J Oncol 21:153–157PubMed

69.

Covey TM, Edes K, Fitzpatrik FA (2007) Akt activation by arachidonic acid metabolism occurs via oxidation and inactivation of PTEN tumor suppression. Oncogene 26:5784–5792PubMedCrossRef

70.

Dang CT, Dannenberg AJ, Subbaramaiah K, Dickler MN, Moasser MM, Seidman AD, D’Andrea GM, Theodoulou M, Panageas KS, Norton L, Hudis GA (2004) Phase II study of celecoxib and trastuzumab in metastatic breast cancer patients who have progressed after prior trastuzumab-based treatments. Clin Cancer Res 10:4062–4067PubMedCrossRef

71.

Canney PA, Machin MA, Curto J (2006) A feasibility study of the efficacy and tolerability of the combination of Exemestane with the Cox-2 inhibitor Celecoxib in post-menopausal patients with advanced breast cancer. Eur J Cancer 42:2751–2756PubMedCrossRef

72.

Petrakis NL (1986) Physiologic, biochemical, and cytological aspects of nipple aspirate fluids. Breast Cancer Res Treat 8:7–19PubMedCrossRef

73.

Reids RC (2005) Inhibitors of secretory phospholipase A₂ group IIA. Curr Med Chem 12:3011–3026CrossRef

Titel: Nipple aspirate fluids from women with breast cancer contain increased levels of group IIa secretory phospholipase A2
verfasst von: Ferdinando Mannello
Wenyi Qin
Weizhu Zhu
Laura Fabbri
Gaetana A. Tonti
Edward R. Sauter
Publikationsdatum: 01.09.2008
Verlag: Springer US
Erschienen in: Breast Cancer Research and Treatment / Ausgabe 2/2008
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-007-9779-1

Springer Medizin

Nipple aspirate fluids from women with breast cancer contain increased levels of group IIa secretory phospholipase A2

Abstract

Neu im Fachgebiet Onkologie

Labor, CT-Anthropometrie zeigen Risiko für Pankreaskrebs

Viel pflanzliche Nahrung, seltener Prostata-Ca.-Progression

Alter verschlechtert Prognose bei Endometriumkarzinom

Darf man die Behandlung eines Neonazis ablehnen?

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2008

Development of a high sensitivity, nested Q-PCR assay for mouse and human aromatase

Taxane vs. taxane: is the duel at an end? A commentary on a phase-III trial of doxorubicin and docetaxel versus doxorubicin and paclitaxel in metastatic breast cancer: results of the ERASME 3 study

Paget’s disease of the nipple in a population based cohort

Adjuvant chemotherapy for breast cancer: a cost-utility analysis of FEC-D vs. FEC 100

Pharmacokinetics and tolerability of exemestane in combination with raloxifene in postmenopausal women with a history of breast cancer

Is obesity an independent prognosis factor in woman breast cancer?

Neu im Fachgebiet Onkologie

Labor, CT-Anthropometrie zeigen Risiko für Pankreaskrebs

Viel pflanzliche Nahrung, seltener Prostata-Ca.-Progression

Alter verschlechtert Prognose bei Endometriumkarzinom

Darf man die Behandlung eines Neonazis ablehnen?

Update Onkologie